However, we found high KRAS adjMAFs in metastatic sites of patients with a previous diagnosis of KRAS wild‐type CRC and exposed to anti‐EGFR therapy, suggesting clonal selection of KRAS‐mutant cells. The gene discussed is KRAS; the disease is colorectal carcinoma.